Howard I. Hoffen
Known title: DirectorCIK: 0001208810
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Transaction History
| ENS | ▲ Buy | Grant | 67 | $0 | 10/2/2026 | View on chart |
| ENS | ▲ Buy | Grant | 4 | $0 | 10/2/2026 | View on chart |
| ENS | ▲ Buy | Grant | 982 | $0 | 8/14/2026 | View on chart |
| ENS | ▲ Buy | Grant | 57 | $0 | 7/2/2026 | View on chart |
| ENS | ▲ Buy | Grant | 4 | $0 | 7/2/2026 | View on chart |
| ENS | ▲ Buy | Grant | 68 | $0 | 3/27/2026 | View on chart |
| ENS | ▲ Buy | Grant | 4 | $0 | 3/27/2026 | View on chart |
| ENS | ▲ Buy | Grant | 77 | $0 | 12/26/2025 | View on chart |
| ENS | ▲ Buy | Grant | 5 | $0 | 12/26/2025 | View on chart |
| ENS | ▲ Buy | Grant | 105 | $0 | 9/26/2025 | View on chart |
| ENS | ▲ Buy | Grant | 7 | $0 | 9/26/2025 | View on chart |
| ENS | ▲ Buy | Grant | 2,088 | $0 | 8/8/2025 | View on chart |
| ENS | ▲ Buy | Grant | 117 | $0 | 6/27/2025 | View on chart |
| ENS | ▲ Buy | Grant | 8 | $0 | 6/27/2025 | View on chart |
| ENS | ▲ Buy | Grant | 109 | $0 | 3/28/2025 | View on chart |
| ENS | ▲ Buy | Grant | 8 | $0 | 3/28/2025 | View on chart |
| ENS | ▼ Sell | Open Market | 5,001 | $514K | 2/26/2025 | View on chart |
| ENS | ▼ Sell | Other | 0 | $16 | 2/1/2025 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/27/2024 | View on chart |
| ENS | ▲ Buy | Grant | 122 | $0 | 12/27/2024 | View on chart |
| ENS | ▲ Buy | Grant | 7 | $0 | 12/27/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/30/2024 | View on chart |
| ENS | ▲ Buy | Grant | 110 | $0 | 9/30/2024 | View on chart |
| ENS | ▲ Buy | Grant | 7 | $0 | 9/30/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/30/2024 | View on chart |
| ENS | ▲ Buy | Grant | 2,026 | $0 | 8/9/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/28/2024 | View on chart |
| ENS | ▲ Buy | Grant | 97 | $0 | 6/28/2024 | View on chart |
| ENS | ▲ Buy | Grant | 6 | $0 | 6/28/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/28/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/28/2024 | View on chart |
| ENS | ▲ Buy | Grant | 106 | $0 | 3/29/2024 | View on chart |
| ENS | ▲ Buy | Grant | 7 | $0 | 3/29/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/29/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/29/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/29/2024 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/29/2024 | View on chart |
| ENS | ▲ Buy | Grant | 262 | $25K | 1/16/2024 | View on chart |
| ENS | ▲ Buy | Grant | 53 | $0 | 1/16/2024 | View on chart |
| ENS | ▲ Buy | Grant | 99 | $0 | 12/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 5 | $0 | 12/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 248 | $22K | 10/20/2023 | View on chart |
| ENS | ▲ Buy | Grant | 50 | $0 | 10/20/2023 | View on chart |
| ENS | ▲ Buy | Grant | 106 | $0 | 9/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 5 | $0 | 9/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/29/2023 | View on chart |
| ENS | ▲ Buy | Grant | 2,017 | $0 | 8/11/2023 | View on chart |
| ENS | ▲ Buy | Grant | 202 | $23K | 7/19/2023 | View on chart |
| ENS | ▲ Buy | Grant | 40 | $0 | 7/19/2023 | View on chart |
| ENS | ▲ Buy | Grant | 68 | $0 | 6/30/2023 | View on chart |
| ENS | ▲ Buy | Grant | 3 | $0 | 6/30/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/30/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/30/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/30/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/30/2023 | View on chart |
| ENS | ▲ Buy | Grant | 274 | $23K | 4/18/2023 | View on chart |
| ENS | ▲ Buy | Grant | 55 | $0 | 4/18/2023 | View on chart |
| ENS | ▲ Buy | Grant | 85 | $0 | 3/31/2023 | View on chart |
| ENS | ▲ Buy | Grant | 3 | $0 | 3/31/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/31/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/31/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/31/2023 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 3/31/2023 | View on chart |
| ENS | ▲ Buy | Grant | 283 | $23K | 1/20/2023 | View on chart |
| ENS | ▲ Buy | Grant | 57 | $0 | 1/20/2023 | View on chart |
| ENS | ▲ Buy | Grant | 100 | $0 | 12/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 3 | $0 | 12/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 12/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 386 | $23K | 10/14/2022 | View on chart |
| ENS | ▲ Buy | Grant | 77 | $0 | 10/14/2022 | View on chart |
| ENS | ▲ Buy | Grant | 127 | $0 | 9/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 2 | $0 | 9/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 9/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 3,318 | $0 | 8/12/2022 | View on chart |
| ENS | ▲ Buy | Grant | 397 | $23K | 7/14/2022 | View on chart |
| ENS | ▲ Buy | Grant | 79 | $0 | 7/14/2022 | View on chart |
| ENS | ▲ Buy | Grant | 1 | $0 | 6/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 0 | $0 | 6/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 115 | $0 | 6/30/2022 | View on chart |
| ENS | ▲ Buy | Grant | 327 | $23K | 4/15/2022 | View on chart |
| ENS | ▲ Buy | Grant | 65 | $0 | 4/15/2022 | View on chart |
| ENS | ▲ Buy | Grant | 89 | $0 | 3/25/2022 | View on chart |
| ENS | ▲ Buy | Grant | 85 | $0 | 12/31/2021 | View on chart |
| JSPR | ▲ Buy | Option Exercise | 2,300,000 | — | 9/24/2021 | View on chart |
| ENS | ▲ Buy | Grant | 89 | $0 | 9/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
EnerSys Q2 Recap and Data Center Focus
Recent coverage benchmarks EnerSys' Q2 performance against renewable energy peers and highlights its exposure to data centers and defense. The stock is also mentioned in lists of value stocks and industrial peers, though it has been falling alongside other companies in the sector. These articles provide context on the company's current market position and sector trends.
EnerSys Q2 Recap and Data Center Focus. Recent coverage benchmarks EnerSys' Q2 performance against renewable energy peers and highlights its exposure to data centers and defense. The stock is also mentioned in lists of value stocks and industrial peers, though it has been falling alongside other companies in the sector. These articles provide context on the company's current market position and sector trends.